KRAS and neoplasm: CD8+ T cells that recognize KRAS G12V5–14 have been isolated from peripheral blood of HLA-A*02:01+ healthy donors and patients with pancreatic cancer and shown to kill tumor cells, albeit at very high effector to target ratios (Kubuschok et al. 2006, Rive et al. 2020).